Glaukos Earnings: Whether the iDose Launch Can Justify What's Already Been Priced In
Glaukos Corporation (GKOS) reports second-quarter 2026 earnings after the close on July 29, 2026, with analysts expecting a loss of $0.28 per share. The central question: can the ophthalmic medical device maker continue its recent streak of earnings surprises while demonstrating progress toward profitability? With the stock up more than 30% year-to-date and trading at $151.33, investors will be watching closely for signs that GKOS can sustain momentum in a market environment where sentiment has become increasingly selective.
Part 1: Earnings Preview
Glaukos Corporation develops and commercializes ophthalmic medical devices, primarily focused on minimally invasive surgical solutions for glaucoma and corneal health. The company's portfolio includes its flagship iStent family of micro-bypass stents and the iDose TR travoprost implant, positioning it as a key player in the growing market for micro-invasive glaucoma surgery (MIGS).
For the second quarter ending June 2026, analysts expect GKOS to report a loss of $0.28 per share on consensus estimates from 5 analysts, with a range from -$0.31 to -$0.24. The company most recently reported -$0.18 per share for Q1 2026, beating estimates by 40%. Year-over-year, the Q2 estimate represents a 16.67% deterioration compared to the -$0.24 reported in Q2 2025, though this comparison reflects the company's ongoing investment phase as it scales commercial operations.
Three key themes define this earnings story:
Commercial Execution and Market Penetration — Investors will scrutinize revenue growth across GKOS's product portfolio, particularly adoption rates for iDose TR, which received FDA approval in 2023. The company's ability to expand its sales force and drive procedure volumes in both domestic and international markets remains critical to the growth narrative.
Path to Profitability — With full-year 2026 EPS estimates of -$0.57 representing a significant improvement from prior expectations of -$0.90, and 2027 estimates calling for the company to turn profitable at +$0.46, investors are focused on whether GKOS can demonstrate operating leverage and margin expansion as revenues scale.
Regulatory and Pipeline Progress — Any updates on clinical trials, regulatory submissions, or new product development will be closely watched, as GKOS's long-term value proposition depends on expanding its addressable market beyond current glaucoma indications.
Analyst sentiment heading into the release is overwhelmingly bullish, with 13 Strong Buy ratings and an average price target of $164.50, implying 8.7% upside from current levels. The consensus view suggests GKOS is executing well on its commercial strategy, though the market will be looking for concrete evidence that the company can meet its ambitious profitability timeline while maintaining growth momentum.
Part 2: Historical Earnings Performance
Glaukos has demonstrated a mixed but improving pattern of earnings performance over the past four quarters. The company has beaten estimates in three of the last four quarters, with particularly strong surprises in Q3 2025 (+40.74%) and Q1 2026 (+40.00%). The one miss came in Q4 2025, when GKOS reported -$0.28 versus estimates of -$0.22, a -27.27% surprise that interrupted an otherwise positive trend.
The magnitude of beats has been substantial when they occur, with the company exceeding expectations by an average of approximately 29% in the three quarters where it outperformed. This suggests that when GKOS's commercial execution accelerates, it can significantly outpace conservative analyst models. The Q1 2026 result of -$0.18 versus estimates of -$0.30 marked the most recent positive surprise and set a high bar for Q2.
The trend in reported results shows gradual improvement in absolute loss levels over the past year, from -$0.24 in Q2 2025 to -$0.18 in Q1 2026, though with some quarterly volatility. This pattern aligns with the company's stated trajectory toward profitability, though investors will be watching whether Q2 can maintain the momentum from Q1 or if seasonal factors and investment spending create near-term pressure on the bottom line.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $-0.26 | $-0.24 | +7.69% | Beat |
| Sep 2025 | $-0.27 | $-0.16 | +40.74% | Beat |
| Dec 2025 | $-0.22 | $-0.28 | -27.27% | Miss |
| Mar 2026 | $-0.30 | $-0.18 | +40.00% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
GKOS reports after market close, meaning Day 0 reflects pre-announcement trading while Day +1 captures the market's first full reaction to results.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-04-29 | -$2.67 (-2.23%) | $7.07 (5.91%) | +$26.71 (+22.84%) | $14.60 (12.48%) |
| 2026-02-17 | -$2.83 (-2.59%) | $5.20 (4.75%) | +$14.36 (+13.47%) | $18.14 (17.02%) |
| 2025-10-29 | -$0.70 (-0.90%) | $4.12 (5.30%) | +$10.71 (+13.89%) | $16.95 (21.99%) |
| 2025-07-30 | +$0.29 (+0.31%) | $3.74 (3.99%) | -$7.96 (-8.46%) | $11.34 (12.06%) |
| 2025-04-30 | +$0.42 (+0.45%) | $4.19 (4.47%) | -$10.71 (-11.36%) | $8.33 (8.84%) |
| 2025-02-20 | -$3.22 (-2.01%) | $4.73 (2.94%) | -$31.48 (-20.01%) | $18.00 (11.44%) |
| 2024-11-04 | -$0.39 (-0.30%) | $4.81 (3.65%) | -$3.52 (-2.68%) | $6.49 (4.94%) |
| 2024-07-31 | -$0.72 (-0.61%) | $3.71 (3.15%) | +$0.44 (+0.38%) | $11.05 (9.43%) |
| Avg Abs Move | 1.17% | 4.27% | 11.64% | 12.27% |
Historical price action around earnings reveals significant volatility, with an average absolute Day +1 move of 11.64% and an average Day +1 range of 12.27%. The most dramatic reactions have come on positive surprises: the April 2026 report generated a +22.84% Day +1 move, while the February 2026 report produced a +13.47% gain. Conversely, the February 2025 earnings triggered a sharp -20.01% decline, demonstrating that misses can be punished severely.
The Day 0 moves have been relatively muted at 1.17% on average, which is typical for after-hours reporters where initial reactions are limited by lower liquidity. The real price discovery occurs on Day +1, when the stock has shown a tendency toward large directional moves that often exceed 10%. Recent quarters show a pattern of strong positive reactions when the company beats estimates, suggesting the market is rewarding execution and progress toward profitability targets.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 24) |
| Expected Move | $25.59 (16.88%) |
| Expected Range | $125.97 to $177.14 |
| Implied Volatility | 102.20% |
The options market is pricing an expected move of 16.88% for the upcoming earnings release, which is substantially higher than the historical average Day +1 move of 11.64%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction, possibly reflecting increased uncertainty around the company's ability to maintain its recent positive momentum or concerns about guidance in a challenging macro environment.
Part 3: What Analysts Are Saying
Analyst sentiment on Glaukos is overwhelmingly bullish, with the stock carrying an average recommendation of 4.80 out of 5.00 — firmly in Strong Buy territory. The current consensus includes 13 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with zero sell ratings across the 15 analysts covering the stock. This represents an improved sentiment trend from one month ago, when the average recommendation stood at 4.79 with 12 Strong Buys.
The average price target of $164.50 implies 8.7% upside from the current price of $151.33, with a range spanning from a low of $138.00 to a high of $190.00. The wide target range reflects differing views on the company's execution timeline and the speed at which it can achieve profitability, though even the most conservative target sits near current levels, suggesting limited downside risk in the analyst community's view.
The strengthening consensus — with one additional Strong Buy rating added in the past month — indicates growing confidence in GKOS's commercial trajectory and its ability to deliver on financial targets. The near-unanimous bullish stance suggests analysts believe the company is well-positioned to capitalize on the expanding MIGS market and that current valuation levels do not fully reflect the earnings power of the business as it scales toward profitability in 2027.
Part 4: Technical Picture
The Barchart Technical Opinion currently shows an 88% Buy signal, down slightly from 100% Buy one week ago but unchanged from 88% Buy one month ago. This indicates the technical setup remains constructive heading into earnings, though with some very recent softness.
Timeframe Analysis:
- Short-term (50% Buy): Moderate buy signal suggests near-term momentum has cooled somewhat, likely reflecting consolidation after the strong year-to-date rally
- Medium-term (100% Buy): Maximum buy signal indicates intermediate-term trend remains firmly positive and supportive
- Long-term (100% Buy): Maximum buy signal confirms the longer-term uptrend is intact and well-established
Trend Characteristics: The combination of Maximum strength and Average direction suggests GKOS is in a powerful uptrend with normal pullbacks and consolidation patterns — a healthy technical environment for a stock approaching earnings.
The stock is trading at $151.33, positioned above its 20-day ($151.52 — essentially on this level), 50-day ($136.78), 100-day ($127.14), and 200-day ($116.00) moving averages, confirming the strength of the longer-term uptrend. However, the stock has slipped slightly below its 5-day ($152.36) and 10-day ($153.94) moving averages, indicating some near-term consolidation after recent gains.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $152.36 | 50-Day MA | $136.78 |
| 10-Day MA | $153.94 | 100-Day MA | $127.14 |
| 20-Day MA | $151.52 | 200-Day MA | $116.00 |
The technical setup heading into earnings is generally supportive, with the stock maintaining its position above all major long-term moving averages and showing strong medium- and long-term momentum. The 30% year-to-date gain has the stock well above its rising 200-day moving average, providing a technical cushion. However, the recent slip below short-term moving averages and the pullback in the short-term opinion signal to 50% Buy suggest some profit-taking or caution ahead of the report. The elevated options-implied move of 16.88% indicates the market is bracing for significant volatility, which could work in either direction depending on results and guidance. Overall, the technical picture suggests GKOS has room to run higher on a positive surprise, but the recent consolidation also means a disappointment could trigger a sharper pullback from current levels.
